Corvus Pharmaceuticals (CRVS)

• Market cap: $1.56B
• 1 day: -0.53%
• 5 days: -9.15%
• 1 month: 187.08%
• 3 months: 133.25%
• 6 months: 273.2%
• Year to date: 154.92%
• 1 year: 279.27%
• 5 years: 412.64%
• 10 years: 30.95%
• Sector: Healthcare
• Industry: Biotechnology

About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Employees: 31